Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
2001 5
2002 2
2003 2
2004 1
2005 1
2006 3
2007 9
2008 1
2009 9
2010 4
2011 6
2012 1
2013 6
2014 10
2015 11
2016 11
2017 8
2018 6
2019 6
2020 10
2021 4
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

104 results
Results by year
Filters applied: . Clear all
Page 1
Hypoxia and hypoxia response-associated molecular markers in esophageal cancer: A systematic review.
Peerlings J, Van De Voorde L, Mitea C, Larue R, Yaromina A, Sandeleanu S, Spiegelberg L, Dubois L, Lambin P, Mottaghy FM. Peerlings J, et al. Methods. 2017 Nov 1;130:51-62. doi: 10.1016/j.ymeth.2017.07.002. Epub 2017 Jul 10. Methods. 2017. PMID: 28705470 Review.
CONCLUSION: Evaluation of tumor micro-environmental conditions, such as intratumoral hypoxia, is important to predict treatment outcome and efficacy. Promising non-invasive imaging-techniques have been suggested to assess tumor hypoxia and hypoxia-associated …
CONCLUSION: Evaluation of tumor micro-environmental conditions, such as intratumoral hypoxia, is important to predict treatment outco …
Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles.
Peeters SG, Zegers CM, Yaromina A, Van Elmpt W, Dubois L, Lambin P. Peeters SG, et al. Q J Nucl Med Mol Imaging. 2015 Mar;59(1):39-57. Epub 2014 Dec 17. Q J Nucl Med Mol Imaging. 2015. PMID: 25517080 Review.
Furthermore, multiple studies describe the prognostic value of hypoxia PET imaging and the ability to monitor hypoxia during treatment. ...Also the feasibility studies for hypoxia guided intensity modulated radiation therapy and the patient stratification for …
Furthermore, multiple studies describe the prognostic value of hypoxia PET imaging and the ability to monitor hypoxia during t …
New ways to image and target tumour hypoxia and its molecular responses.
Dubois LJ, Niemans R, van Kuijk SJ, Panth KM, Parvathaneni NK, Peeters SG, Zegers CM, Rekers NH, van Gisbergen MW, Biemans R, Lieuwes NG, Spiegelberg L, Yaromina A, Winum JY, Vooijs M, Lambin P. Dubois LJ, et al. Radiother Oncol. 2015 Sep;116(3):352-7. doi: 10.1016/j.radonc.2015.08.022. Epub 2015 Aug 28. Radiother Oncol. 2015. PMID: 26324018 Free article. Review.
Tumour hypoxia and its molecular responses have been shown to be associated with poor prognosis. ...This review gives an overview of recent literature on hypoxia imaging markers currently used in clinical trials. Furthermore, recent progress made in targeting hyp
Tumour hypoxia and its molecular responses have been shown to be associated with poor prognosis. ...This review gives an overview of …
Mitochondrial Dysfunction Inhibits Hypoxia-Induced HIF-1α Stabilization and Expression of Its Downstream Targets.
van Gisbergen MW, Offermans K, Voets AM, Lieuwes NG, Biemans R, Hoffmann RF, Dubois LJ, Lambin P. van Gisbergen MW, et al. Front Oncol. 2020 May 19;10:770. doi: 10.3389/fonc.2020.00770. eCollection 2020. Front Oncol. 2020. PMID: 32509579 Free PMC article.

Increased glycolysis was observed for cytoplasmic 143B mutant hybrid (m.3243A>G, >94.5%) cells (p < 0.05) and 143B mitochondrial DNA (mtDNA) depleted cells (p < 0.05). Upon hypoxia (0.2%, 16 h), genetic or pharmacological oxidative phosphorylation

Increased glycolysis was observed for cytoplasmic 143B mutant hybrid (m.3243A>G, >94.5%) cells (p < 0.05) and 143B mitochond

Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape.
Hamis S, Kohandel M, Dubois LJ, Yaromina A, Lambin P, Powathil GG. Hamis S, et al. PLoS Comput Biol. 2020 Aug 3;16(8):e1008041. doi: 10.1371/journal.pcbi.1008041. eCollection 2020 Aug. PLoS Comput Biol. 2020. PMID: 32745136 Free PMC article.
Hypoxia-activated prodrugs (HAPs) present a conceptually elegant approach to not only overcome, but better yet, exploit intra-tumoural hypoxia. ...
Hypoxia-activated prodrugs (HAPs) present a conceptually elegant approach to not only overcome, but better yet, exploit intra-tumoura
Non-invasive imaging prediction of tumor hypoxia: A novel developed and externally validated CT and FDG-PET-based radiomic signatures.
Sanduleanu S, Jochems A, Upadhaya T, Even AJG, Leijenaar RTH, Dankers FJWM, Klaassen R, Woodruff HC, Hatt M, Kaanders HJAM, Hamming-Vrieze O, van Laarhoven HWM, Subramiam RM, Huang SH, O'Sullivan B, Bratman SV, Dubois LJ, Miclea RL, Di Perri D, Geets X, Crispin-Ortuzar M, Apte A, Deasy JO, Oh JH, Lee NY, Humm JL, Schöder H, De Ruysscher D, Hoebers F, Lambin P. Sanduleanu S, et al. Radiother Oncol. 2020 Dec;153:97-105. doi: 10.1016/j.radonc.2020.10.016. Epub 2020 Nov 1. Radiother Oncol. 2020. PMID: 33137396 Free article.
BACKGROUND: Tumor hypoxia increases resistance to radiotherapy and systemic therapy. ...A tumor volume-alone model was unable to significantly classify patients as hypoxia-positive/ negative. A significant survival split (P = 0.037) was found between CT-class …
BACKGROUND: Tumor hypoxia increases resistance to radiotherapy and systemic therapy. ...A tumor volume-alone model was unable to sign …
Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma.
Zegers CM, van Elmpt W, Hoebers FJ, Troost EG, Öllers MC, Mottaghy FM, Lambin P. Zegers CM, et al. Acta Oncol. 2015;54(9):1378-84. doi: 10.3109/0284186X.2015.1062913. Epub 2015 Jul 27. Acta Oncol. 2015. PMID: 26213313
BACKGROUND: Tumour hypoxia and a high tumour metabolism increase radioresistance in patients with head and neck squamous cell carcinoma (HNSCC). The aim of this study was to evaluate the correlation between hypoxia ([(18)F]HX4 PET) and glucose metabolism ([(18)F]FDG …
BACKGROUND: Tumour hypoxia and a high tumour metabolism increase radioresistance in patients with head and neck squamous cell carcino …
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.
Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL, Scozzafava A, Supuran CT, Moser I, Jobst G, Busk M, Toustrup K, Overgaard J, Alsner J, Pouyssegur J, Chiche J, Mazure N, Marchiq I, Parks S, Ahmed A, Ashcroft M, Pastorekova S, Cao Y, Rouschop KM, Wouters BG, Koritzinsky M, Mujcic H, Cojocari D. Pettersen EO, et al. J Enzyme Inhib Med Chem. 2015;30(5):689-721. doi: 10.3109/14756366.2014.966704. Epub 2014 Oct 27. J Enzyme Inhib Med Chem. 2015. PMID: 25347767 Review.
Low density quantitative real-time polymerase chain reaction (qPCR)-based assays were developed measuring multiple hypoxia-responsive markers in parallel to identify tumour hypoxia-related patterns of gene expression. As possible targets for new therapy two main reg …
Low density quantitative real-time polymerase chain reaction (qPCR)-based assays were developed measuring multiple hypoxia-responsive …
Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.
Salem A, Asselin MC, Reymen B, Jackson A, Lambin P, West CML, O'Connor JPB, Faivre-Finn C. Salem A, et al. J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx160. J Natl Cancer Inst. 2018. PMID: 28922791 Review.
This review will summarize the role of hypoxia, highlight the potential of hypoxia as a therapeutic target, and outline past and ongoing hypoxia-targeted therapy trials in NSCLC. Evidence supporting radiotherapy dose painting based on hypoxia imaging w …
This review will summarize the role of hypoxia, highlight the potential of hypoxia as a therapeutic target, and outline past a …
Hypoxia-Activated Prodrug Derivatives of Carbonic Anhydrase Inhibitors in Benzenesulfonamide Series: Synthesis and Biological Evaluation.
Anduran E, Aspatwar A, Parvathaneni NK, Suylen D, Bua S, Nocentini A, Parkkila S, Supuran CT, Dubois L, Lambin P, Winum JY. Anduran E, et al. Molecules. 2020 May 18;25(10):2347. doi: 10.3390/molecules25102347. Molecules. 2020. PMID: 32443462 Free PMC article.
Hypoxia, a common feature of solid tumours' microenvironment, is associated with an aggressive phenotype and is known to cause resistance to anticancer chemo- and radiotherapies. Tumour-associated carbonic anhydrases isoform IX (hCA IX), which is upregulated under hypox
Hypoxia, a common feature of solid tumours' microenvironment, is associated with an aggressive phenotype and is known to cause resist
104 results